What results from clinical trials support polivy's use?

Short answer: yes. The clinical-trial evidence supporting Polivy (polatuzumab vedotin) comes from two key trials in diffuse large B-cell lymphoma (DLBCL), one in relapsed/refractory disease and one in the first-line setting.

- Relapsed/refractory DLBCL (polatuzumab vedotin + bendamustine + rituximab vs bendamustine + rituximab)
- Trial: GO29365
- Design: adults with relapsed/refractory DLBCL after 1–3 prior therapies were randomized to polatuzumab vedotin with BR vs BR alone.
- Key findings: adding polatuzumab vedotin improved response rates and duration of response and prolonged progression-free survival compared with BR alone. The combination had a manageable safety profile but was associated with more hematologic toxicity (e.g., cytopenias) and neuropathy, as well as increased infection risk.
- Regulatory impact: supported FDA labeling for Polivy in combination with BR for relapsed/refractory DLBCL after prior therapies.

- First-line DLBCL (polatuzumab vedotin + rituximab + cyclophosphamide + doxorubicin + prednisone, with polatuzumab replacing vincristine)
- Trial: POLARIX
- Design: patients were randomized to R-CHP plus polatuzumab vedotin vs standard R-CHOP (vincristine-containing) in newly diagnosed DLBCL.
- Key findings: in the polatuzumab arm, progression-free survival was improved versus standard R-CHOP (the primary endpoint). Overall survival benefit was not statistically definitive at the initial reporting. Safety profile showed more hematologic toxicity (e.g., neutropenia, febrile neutropenia, anemia), as well as neuropathy and certain infections, but overall was considered manageable.
- Regulatory impact: supported use of Polivy in first-line DLBCL in the R-CHP backbone (replacing vincristine) in appropriate patients.

If you’d like, I can pull exact numbers (percentages, hazard ratios, confidence intervals) from these trials or provide a quick side-by-side summary by setting (R/R vs. first-line).